PMID- 16898965
OWN - NLM
STAT- MEDLINE
DCOM- 20061010
LR  - 20091119
IS  - 0141-9854 (Print)
IS  - 0141-9854 (Linking)
VI  - 28
IP  - 4
DP  - 2006 Aug
TI  - Expression of the vascular endothelial growth factor receptors 1 and 2 in acute 
      myeloid leukemia: incidence and feasibility of immunohistochemical staining.
PG  - 254-8
AB  - Vascular endothelial growth factor (VEGF) and its receptor tyrosine kinases, 
      VEGFR-1 and VEGFR-2, are important therapeutic targets for various cancers 
      including AML. Paraffin-embedded bone marrow samples (PE-BM) are, in most cases, 
      the only tissue accessible to perform retrospective analyses of novel targets 
      such as VEGF and/or its receptors. As a result, it limits our options to 
      immunohistochemistry (IHS), or more expensive and less practical techniques such 
      as enzyme-linked immunosorbent assay (ELISA) or fluorescence in situ 
      hybridization (FISH). We analyzed the feasibility of IHS to measure VEGFR-1 and 
      VEGFR-2 expression in 28 AML samples using monoclonal antibodies (moAbs) against 
      Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2). Medical records were reviewed for 
      relevant clinical information. Expression of VEGFR-1 (+) and VEGFR-2 (+) were 
      seen in 25% (7/28) and 43% (12/28) respectively. Forty-six percent (13/28) were 
      dual-negatives for VEGFR-1 and VEGFR-2; 14% (4/28) were dual-positives for 
      VEGFR-1 and VEGFR-2. An inferior survival was observed in patients whose 
      myeloblasts express either VEGFR-1 (+) or VEGFR-2 (+), or both. Determination of 
      expression of VEGF receptors (1 and 2) by IHS in PE-BM tissue is feasible. 
      Prospective comparison of IHC to flow cytometry or other molecular techniques, 
      and assessment of the prognostic significance of VEGF receptors in AML patients 
      is warranted.
FAU - Kharfan-Dabaja, M A
AU  - Kharfan-Dabaja MA
AD  - Section of Hematology-Oncology and OU cancer Center, University of Oklahoma 
      Health Sciences Center, Oklahoma City, OK, USA. kharfama@moffitt.usf.edu
FAU - Patel, S A
AU  - Patel SA
FAU - Osunkoya, A O
AU  - Osunkoya AO
FAU - Kojouri, K
AU  - Kojouri K
FAU - Kamble, R
AU  - Kamble R
FAU - Yang, J
AU  - Yang J
FAU - Hashmi, M
AU  - Hashmi M
FAU - Ozer, H
AU  - Ozer H
FAU - Selby, G B
AU  - Selby GB
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Lab Haematol
JT  - Clinical and laboratory haematology
JID - 7907061
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Marrow/*chemistry
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Leukemia, Myeloid, Acute/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Vascular Endothelial Growth Factor Receptor-1/*analysis
MH  - Vascular Endothelial Growth Factor Receptor-2/*analysis
EDAT- 2006/08/11 09:00
MHDA- 2006/10/13 09:00
CRDT- 2006/08/11 09:00
PHST- 2006/08/11 09:00 [pubmed]
PHST- 2006/10/13 09:00 [medline]
PHST- 2006/08/11 09:00 [entrez]
AID - CLH802 [pii]
AID - 10.1111/j.1365-2257.2006.00802.x [doi]
PST - ppublish
SO  - Clin Lab Haematol. 2006 Aug;28(4):254-8. doi: 10.1111/j.1365-2257.2006.00802.x.